gms | German Medical Science

GMS Current Posters in Otorhinolaryngology - Head and Neck Surgery

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e.V. (DGHNOKHC)

ISSN 1865-1038

Artikel

Artikel empfehlen

The use of Omalizumab in the treatment of nasal polyps

Poster Allergologie / Umweltmedizin / Immunologie

Suche in Medline nach

  • corresponding author Anna Yakinthou - Praxis, Thessaloniki, Griechenland
  • Drosos Tsavlis - Praxis, Thessaloniki, Griechenland
  • Ioannis Megas - Praxis, Thessaloniki, Griechenland

GMS Curr Posters Otorhinolaryngol Head Neck Surg 2015;11:Doc009

doi: 10.3205/cpo000974, urn:nbn:de:0183-cpo0009749

Veröffentlicht: 16. April 2015

© 2015 Yakinthou et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Abstract

It is often that patients with nasal polyps may suffer from asthma. Both, nasal polyps and asthma, share the same features, inflammation, eosinophilia and local IgE formation. Omalizumab, as an anti-IgE mAb, is proven to be effective in treating allergic asthma. Could be, also, a treatment in nasal polyps.

Our target is to investigate the clinical efficacy of omalizumab in nasal polyps.

We have 7 patients with massive polyposis and asthma. Omalizumab was given at 2-or 4-week intervals, based on patient's body weight and IgE levels. After 16 weeks, we had an endoscopical reduction in nasal polyps, an improvement in spirometry, a reduction of nasal corticosteroids use and an improvement in the quality of life.

Omalizumab is effective in the symptoms of nasal congestion, anterior rhinorrhea, loss of smell, wheezing and dyspnea. This could be due to the local IgE formation in nose and lungs.

Der Erstautor gibt keinen Interessenkonflikt an.